Vectrus, Inc. (VEC) – Business Wire
-
Philip Morris International Announces Unconditional Offer for Vectura Group PLC
-
Novaremed Expands its Pipeline of Non-opioid Treatment Candidates for Chronic Pain Indications Through Acquisition of Metys Pharmaceuticals
-
Philip Morris International Enters Tender Period with Vectura Shareholders Following Unanimous Recommendation by Vectura Board
-
Philip Morris International Inc. Reports 2021 Second-Quarter Reported Diluted EPS of $1.39—Including Charges for Saudi Arabia Customs Assessments and Exit Costs—and Adjusted Diluted EPS of $1.57,
-
Philip Morris International Inc. Announces Firm Offer to Acquire Vectura Group plc; Acquisition Accelerates PMI’s Beyond Nicotine Strategy and Expands its Product Pipeline Development Capabilities i
-
Kinaset Therapeutics Launches with a $40M Series A Financing to Develop Novel Therapeutics for Respiratory Diseases and an Exclusive Global License Agreement with Vectura Group for KN-002 (VR588), a N
Back to VEC Stock Lookup
